Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response
Authors:
Open Access
- 3 December 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-9
Abstract
The SWI/SNF chromatin remodeling complex has been found mutated in a wide range of human cancers, causing alterations in gene expression patterns, proliferation and DNA damage response that have been linked to poor clinical prognosis. Here, we investigated weather knockdown of ARID1B, one of two mutually exclusive subunits within the SWI/SNF complex, can sensitize colorectal cancer cell lines mutated in the other subunit, ARID1A, to ionizing radiation (IR). ARID1A-mutated colorectal cancer (CRC) cell lines are selectively sensitized to IR after siRNA mediated ARID1B depletion, as measured by clonogenic survival. This is characterized by a decrease in the surviving cell fraction to 87.3% ± 2.1%, 86.0% ± 1.1% and 77.2% ± 1.5% per 1 Gy compared with control siRNA exposed cells in the dose range of 0–6 Gy for the LS180, RKO and SW48 lines, respectively (p < 0.0001, F-test). The magnitude of this dose modifying effect was significantly larger in ARID1A mutated than in non-mutated cell lines (Spearman rank correlation rs = 0.88, p = 0.02). Furthermore, initial formation of RAD51 foci at 4 h after IR, as a measure for homologous recombination repair, was significantly reduced in ARID1A-mutant CRC cell lines but not in the majority of wildtype lines nor in fibroblasts. These findings open up perspectives for targeting ARID1B in combination with radiotherapy to improve outcomes of patients with ARID1A-mutant CRC.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft, Germany (DFG) through the GRK 1739
This publication has 20 references indexed in Scilit:
- Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor TherapyClinical Cancer Research, 2019
- Targeting of BRM Sensitizes BRG1-Mutant Lung Cancer Cell Lines to RadiotherapyMolecular Cancer Therapeutics, 2019
- The SWI/SNF complex subunit genes: Their functions, variations, and links to risk and survival outcomes in human cancersCritical Reviews in Oncology/Hematology, 2018
- ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1ANature Communications, 2016
- Clinicopathological significance of ARID1B in breast invasive ductal carcinomaHistopathology, 2015
- Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiencyHuman Pathology, 2014
- ARID1B is a specific vulnerability in ARID1A-mutant cancersNature Medicine, 2014
- Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcriptionCarcinogenesis, 2013
- Mammalian SWI/SNF-A Subunit BAF250/ARID1 Is an E3 Ubiquitin Ligase That Targets Histone H2BMolecular and Cellular Biology, 2010
- Distinct roles for the RSC and Swi/Snf ATP-dependent chromatin remodelers in DNA double-strand break repairGenes & Development, 2005